Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07230652 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

Name: A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 — clinical trial record (NCT07230652)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorLuye Pharma Group Ltd.

Started2025-08-20

View on ClinicalTrials.gov ↗

Record status

This record was last updated November 19, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-11-18

Study Status v1

Re-verified, no change to tracked fields

2025-11-14

Original filing

Luye Pharma Group Ltd.

16 trials monitored

See all monitored trials

Alzheimer's Disease

1,140 trials monitored

See 62 trials at risk

Schizophrenia

675 trials monitored

See 32 trials at risk

This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.

Trial Details

NCT Number	NCT07230652
Lead Sponsor	Luye Pharma Group Ltd.
Conditions	Schizophrenia, Alzheimer's Disease Psychosis
Enrollment	40 participants
Start Date	2025-08-20
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-11-19